title: Tachykinin NK2 receptor and functional mechanisms in human colon: changes with indomethacin and in diverticular disease and ulcerative colitis.
abstract: Neurokinin A (NKA) is an important spasmogen in human colon. We examined inflammatory disease-related changes in the tachykinin NK(2) receptor system in human sigmoid colon circular muscle, using functional, radioligand binding, and quantitative reverse transcription-polymerase chain reaction methods. In circular muscle strips, indomethacin enhanced contractile responses to NKA (p < 0.01) and to the NK(2) receptor-selective agonist [Lys(5),MeLeu(9),Nle(10)]-NKA(4-10) (p < 0.05) in both normal and acute diverticular disease (DD) specimens, indicating NK(2) receptor-mediated release of relaxant prostanoids. Contractile responses to both tachykinins were reduced in strips from DD (p < 0.001) and ulcerative colitis (UC) (p < 0.05) specimens. Responses to acetylcholine were no different in other strips from the same disease patients, demonstrating that the change in responsiveness to tachykinins in disease is specifically mediated by the NK(2) receptor. In membranes from UC specimens, receptor affinity for (125)I-NKA (median K(D) 0.91 nM, n = 16) was lower (p < 0.01) than that in age-matched control specimens (K(D) 0.55 nM, n = 40), whereas K(D) (0.65 nM, n = 28) in DD was no different from control. No disease-related changes in receptor number (B(max)) were found (mean, 2.0-2.5 fmol/mg of wet weight tissue), suggesting that the reduced contractile responses in disease are not due to a loss of receptor number. Different mechanisms may account for the reduced contractility in DD compared with UC. A gender-related difference in receptor density was seen in controls, with B(max) lower in females (1.77 fmol/mg, n = 15) than in males (2.60 fmol/mg, n = 25, p = 0.01). In contrast, no gender-related differences were seen in NK(2) receptor mRNA in control colonic muscle, indicating that the gender difference is a post-translational event.
authors.affiliation: Department of Pharmacology, School of Medical Sciences, University of New South Wales, Sydney 2052, NSW, Australia.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Burcher
authors.forename: Fei
authors.initials: F
authors.lastname: Shang
authors.forename: Fiona J
authors.initials: FJ
authors.lastname: Warner
authors.forename: Qin
authors.initials: Q
authors.lastname: Du
authors.forename: David Z
authors.initials: DZ
authors.lastname: Lubowski
authors.forename: Denis W
authors.initials: DW
authors.lastname: King
authors.forename: Lu
authors.initials: L
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003093:Colitis, Ulcerative / Q000378:metabolism / Q000503:physiopathology*; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004241:Diverticulum, Colon / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D015288:Neurokinin A / Q000031:analogs & derivatives / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D018041:Receptors, Neurokinin-2 / Q000819:agonists / Q000235:genetics / Q000502:physiology*
chemical_list: D010446:Peptide Fragments; D012333:RNA, Messenger; D018041:Receptors, Neurokinin-2; C083383:neurokinin A (4-10), Lys(5)-MeLeu(9)-Nle(10)-; D015288:Neurokinin A; D007213:Indomethacin